Back to search results

Mindful Self-Compassion for Anxiety and Depression: Delivery Method Study

This study is testing an 8-week Mindful Self-Compassion training program to see how effective it is for people with anxiety disorders (like generalized anxiety disorder, social anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder. Researchers want to compare if receiving the training in-person or through video-conference makes a difference in reducing anxiety and depression symptoms. You might be able to join if you are 18-65 years old, have one of these conditions, and score low on self-compassion. The study will measure changes in self-critical thoughts and anxiety/depression levels after 8 weeks.

Study design
This is an interventional study comparing two ways of delivering Mindful Self-Compassion training. It plans to enroll 80 participants.
What's involved
You would participate in an 8-week Mindful Self-Compassion training and attend all testing visits.
Compensation
Not stated in the trial record.
Follow-up
Your self-critical thoughts and anxiety/depression levels will be measured at 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07028216

Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method

Recruiting
NAAges 18–65InterventionalTreatment
Georgetown University
~80 participants
Updated 2026-05-05 on ClinicalTrials.gov
What's tested:Mindful Self-Compassion

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Self-Critical Rumination Scale (SCRS)
Measured over 8 weeks
+1 more outcome measured

Conditions

Anxiety Disorders
Generalized Anxiety Disorder
Social Anxiety Disorder
Panic Disorder
Agoraphobia
Major Depressive Disorder
Persistent Depressive Disorder (Dysthymia)

Explore related trials

AgoraphobiaGeneralized Anxiety DisorderPanic DisorderPersistent depressive disorderSocial Anxiety DisorderUnipolar Depression

Where it's being run

1 sites across 1 states
District of Columbia1

Study leadership

  • Elizabeth Hoge, MD · PRINCIPAL_INVESTIGATOR · Georgetown University

Who to contact

Charisma Study Coordinator
[email protected]
202-687-7283
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current
Must score low on self-compassion, as measured by the self-compassion scale
Must understand study procedure and willing to participate in all testing visits, and treatment as assigned
Must be able to give informed consent to the study procedures

Exclusion

Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit
A serious medical condition that may result in surgery or hospitalization.
A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment
Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).
Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.
Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial.
Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy).
Individuals who have completed a course of MSC or an equivalent meditation training in the last year.
Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.
Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and/or labs.
Adults unable to consent
Pregnant women
Prisoners

What this trial measures

  • Self-Critical Rumination Scale (SCRS)8 weeks

    10-item questionnaire that measures ruminative processes related to self-critical thoughts.

  • Hospital Anxiety and Disease Scale (HADS)8 weeks

    Self-report questionnaire of anxiety and depression symptoms, 14 items using 4-point likert scale